OpenAlex Citation Counts

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS^G12C with Demonstrable CNS Penetration
Jason G. Kettle, Sharan K. Bagal, Derek Barratt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9147-9160
Closed Access | Times Cited: 16

Showing 16 citing articles:

Accurate prediction of Kp,uu,brain based on experimental measurement of Kp,brain and computed physicochemical properties of candidate compounds in CNS drug discovery
Yongfen Ma, Mengrong Jiang, Huma Javeria, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24304-e24304
Open Access | Times Cited: 9

Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer
Yanguo Shang, M. Pang, Shengnan Fu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117391-117391
Closed Access | Times Cited: 1

Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer
Yongfeng Shang, Shengnan Fu, M. Pang, et al.
(2025)
Closed Access

Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations
William McCoull, Clare Thomson, Erin Braybrooke, et al.
Journal of Medicinal Chemistry (2025)
Closed Access

Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1
Simon C. C. Lucas, Alexander G. Milbradt, J. Henry Blackwell, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11209-11225
Closed Access | Times Cited: 3

KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Min Tang, Yijun Wu, Xiufeng Bai, et al.
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 683-695
Open Access | Times Cited: 2

Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
Clare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1

Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization
Jian-Tao Shi, Su-Juan Hou, Lei Cheng, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107467-107467
Closed Access

Exploring monocyclic core: Discovery of pyrrol-2-one derivatives as a new series of potent MCHR1 antagonists with in vivo efficacy
Murugaiah A. M. Subbaiah, Umasankar Mandal, Vidya Patankar, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116686-116686
Closed Access

We are MedChem: The Frontiers in Medicinal Chemistry 2024
Matthias Schiedel, Philipp Barbie, Felix Pape, et al.
ChemMedChem (2024)
Closed Access

Preclinical evaluation of targeted therapies for central nervous system metastases
Alexander J. Pfeil, Joshua Hale, Tiger Zhang, et al.
Disease Models & Mechanisms (2024) Vol. 17, Iss. 9
Open Access

CASE HISTORY: THE DISCOVERY OF KRAZATI^® (ADAGRASIB) FOR THE TREATMENT OF KRAS^G12C-MUTATED LUNG CANCER
Matthew A. Marx, Jill Hallin, James G. Christensen, et al.
Medicinal chemistry reviews (2024), pp. 377-396
Closed Access

Insights into direct KRAS inhibition strategies for cancer treatment
Tong Li, Chenglei Gu, Chen Zhou, et al.
Future Medicinal Chemistry (2024), pp. 1-19
Closed Access

Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges
Xin Yang, Xiang Li, Yuelin Zhang, et al.
Future Medicinal Chemistry (2024), pp. 1-5
Closed Access

PET in neurotherapeutic discovery and development
Melissa Chassé, Neil Vasdev
Neurotherapeutics (2024), pp. e00498-e00498
Closed Access

Validation of a good manufacturing practice procedure for the production of [¹¹C]AZD4747, a CNS penetrant KRAS^G12c inhibitor
Miguel A. Cortés González, Antonia Högnäsbacka, Christer Halldin, et al.
Journal of Labelled Compounds and Radiopharmaceuticals (2023) Vol. 67, Iss. 6, pp. 245-249
Open Access

Page 1

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSID	session	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.

Requested Article:

Showing 16 citing articles:

Your Privacy